Stock Ratings / Health Care / NRIX / dividends

VCRE (61) VRDN (45) IDYA (45) DYN (40) ⌘ Pro Terminal →

Nurix Therapeutics Inc. (NRIX) Dividend Safety Gauge & 10-Year DRIP Compounder

$27.12 -0.51% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Nurix Therapeutics Inc. (NRIX) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $2.96B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-7.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NRIX)Realized 20D OHLCV Swing Band: ±11.3%

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (15.1% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $40,809

Est. Year-10 Shareholder Yield: $245/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.5K

Yr 1

$13.2K

Yr 2

$15.2K

Yr 3

$17.6K

Yr 4

$20.2K

Yr 5

$23.3K

Yr 6

$26.8K

Yr 7

$30.8K

Yr 8

$35.5K

Yr 9

$40.8K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NRIX)

✓Walkthrough of NRIX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NRIX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +62.40%📐 HORIZONTAL RANGE

2026-10-30O $26.90H $27.12L $25.97C $27.12VOL 2.31M

RES: $33.77SUP: $21.23SMA50: $24.98SMA200: $20.18

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NRIX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NRIX Butterfly Map → + Track NRIX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +54.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NRIX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NRIX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NRIX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NRIX)

Health Care Rank #570 of 1016 ⚔️ VCRE vs NRIX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NRIX vs. VCRE, VRDN, IDYA, DYN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Nurix Therapeutics Inc. (NRIX) ranks #570 by composite RQD confidence (42/100, grade D-) and #210 by equity capitalization ($2.96B). Within this direct 5-issuer industry benchmark cohort, NRIX leads on earnings valuation at N/A trailing P/E, while IDYA leads on capital efficiency and profitability with -13.8% ROIC and — gross margin. VCRE currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with NRIX at 42/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NRIX ACTIVE Nurix Therapeutics Inc.	D-	42/100	—	—	-35.0%	-0.51%	$2.96B	Benchmark Subject
VCRE Vicore Pharma Holding AB	C-	61/100	—	—	—	+4.56%	$2.87B	/vcre-vs-nrix →
VRDN Viridian Therapeutics Inc.	D	45/100	—	—	-35.0%	+2.18%	$2.81B	/vrdn-vs-nrix →
IDYA IDEAYA Biosciences Inc.	D	45/100	—	—	-13.8%	-3.15%	$3.17B	/idya-vs-nrix →
DYN Dyne Therapeutics Inc.	D-	40/100	—	—	-35.0%	+0.35%	$3.18B	/dyn-vs-nrix →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-11-30 • CIK 0001549595

In its most recent audited fiscal period (FY2025, filed 2025-11-30), Nurix Therapeutics Inc. (NRIX) reported GAAP revenue of $84.0M (+54.0% vs. FY2024 revenue of $54.5M , and +9.1% cumulative change since FY2023) , GAAP net income of -$264.5M, operating cash flow of -$249.5M, and free cash flow of -$263.5M (-44.9% YoY). On the balance sheet, NRIX closed FY2025 with $688.1M in total assets against $0 in total debt (Altman Z-Score: 9.52, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-11-30	$84.0M	-$264.5M	-$249.5M	-$263.5M	$688.1M	—
FY2024 (FY)	2024-11-30	$54.5M	-$193.6M	-$172.6M	-$181.9M	$669.3M	—
FY2023 (FY)	2023-11-30	$77.0M	-$143.9M	-$81.4M	-$81.4M	—	—

3. NRIX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NRIX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Nurix Therapeutics Inc. (NASDAQ: NRIX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $27.12 (-0.51% 1D, market cap $2.96B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NRIX ranks #570 in composite RQD confidence.

How does NRIX compare to VCRE and VRDN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NRIX carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, VCRE (Vicore Pharma Holding AB) holds a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $2.87B) and VRDN (Viridian Therapeutics Inc.) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $2.81B). Among the 5-stock peer group, NRIX leads on earnings multiple (N/A) while IDYA leads on capital efficiency (-13.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NRIX?

Per NRIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-11-30, CIK 0001549595), Nurix Therapeutics Inc. generated $84.0M in revenue (+54.0% YoY), -$264.5M in net income, and -$263.5M in free cash flow against $688.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NRIX trading relative to its 50-day, 200-day, and 52-week technical levels?

NRIX last traded at $27.12 (-0.51% on volume of 2,375,225 shares), positioning the stock +8.57% above its 50-day simple moving average ($24.98) and +34.39% above its 200-day simple moving average ($20.18). Across its 52-week range of $11.67 to $28.23, NRIX sits at the 93.3% percentile with a 14-day RSI of 63.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±11.3% ($24.06 to $30.18).

NRIX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does NRIX pay a dividend and is it safe?

Nurix Therapeutics Inc. (NRIX) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: NRIX RQD Cockpit NRIX 12M Forecast NRIX Earnings & Move NRIX Dividends & DRIP NRIX Insiders & 13F NRIX Whale Options NRIX Profit Sankey NRIX News & Why